Is there an association between disease ignorance and self-rated health? The HUNT Study, a cross-sectional survey

ABSTRACT

Objective: To explore whether awareness versus unawareness of thyroid dysfunction, diabetes mellitus or hypertension is associated with self-rated health.

Design: Large-scale, cross-sectional population-based study. The association between thyroid function, diabetes mellitus and blood pressure and self-rated health was explored by multiple logistic regression analysis.

Setting: The second survey of the Nord-Trøndelag Health Study, HUNT2, 1995–1997.

Participants: 33,734 persons aged 40–70 years.

Primary outcome measures: Logistic regression was used to estimate ORs for good self-rated health as a function of thyroid status, diabetes mellitus status and blood pressure status.

Results: Persons aware of their hypothyroidism, diabetes mellitus or hypertension reported poorer self-rated health than individuals without such conditions. Women with unknown and subclinical hypothyroidism reported better self-rated health than women with normal thyroid status. In women and men, unknown and probable diabetes as well as unknown mild/moderate hypertension was not associated with poorer health. Furthermore, persons with unknown severe hypertension reported better health than normotensive persons.

Conclusions: People with undiagnosed but prevalent hypothyroidism, diabetes mellitus and hypertension often have good self-rated health, while when aware of their diagnoses, they report reduced self-rated health. Use of screening, more sensitive tests and widened diagnostic criteria might have a negative effect on perceived health in the population.

INTRODUCTION

Guidelines for prevention and treatment have been developed for most high-prevalent diseases in western countries aiming for a reduction of morbidity and mortality by interventions mainly in primary healthcare (PHC).

In society, there seems to be an increasing conviction of achievable zero vision regarding risks and diseases. Part of the strategy is to detect risk factors and prediseases in even earlier stages. From a secondary or tertiary healthcare level, this might seem reasonable since intervention on many individuals with specific risk factors presumably can prevent or delay disease or progression of disease. Furthermore, health authorities and hospital clinicians regularly raise concern of the lack of detection of risk factors, of subclinical conditions and of achieving treatment goals. Norwegian studies have shown that guidelines are often difficult to implement and adhere to in PHC. According to guidelines, most individuals would be defined as at risk and resources needed to handle this appropriately could destabilise the entire healthcare system. An American review pointed out knowledge, attitude and behaviour as barriers to physician adherence to clinical guidelines. In an already complex and busy PHC setting, one might expect that resources used for disease prevention and case finding have to compete with resources for handling acknowledged disease. Also, physicians might want to avoid increasing disease-related burden for patients, in line with the old wisdom: “primum non nocere”. Thus, the risk and disease zero visions in society and among politicians are seldom shared by PHC professionals.

When guidelines, mainly based on research from high-risk hospital populations, are applied on low-risk populations in PHC, more healthy individuals are identified as being at risk or are given diagnoses. Also, the widened inclusion criteria for diagnoses in general and
use of more sensitive tests contribute to define more individuals at risk or as unhealthy. The possible undesirable outcomes of such strategies remain unclear.

Self-rated health (SRH) is a valid and widely used measure of general health in epidemiological research. It is associated with several clinical conditions often seen in PHC, with recovery, and is found to predict morbidity, sick leave and disability pension as well as mortality. The majority of studies describing an association between labelling of disease per se and SRH have focused on arterial hypertension. However, one study has indicated reduced SRH among individuals labelled with thyroid dysfunctions.

The aim of this study was to investigate whether persons’ awareness versus unawareness of thyroid dysfunction, diabetes mellitus or hypertension was associated with their SRH, as reported in a population-based health study in Norway.

METHODS

Study population

The data sample in this study stems from the second wave of the Nord-Trøndelag Health Study (HUNT2) conducted in 1995–1997 in the county of Nord-Trøndelag, Norway. All individuals aged 20 years and older, living in the county, were invited (94,194 individuals). In all, 66.7% of men (n=30,860) and 75.5% of women (n=35,280) participated. The survey consisted of questionnaires and measurements, and has previously been described in detail. In our study, we included answers from the main questionnaire and the baseline measurements for persons aged 40–70 years. The age span was chosen because thyroid stimulating hormone (TSH) was analysed in all women and in 50% of men at this age, of a rather low disease burden in people younger than 40 years and of a lower attendance rate under and above this age span. A total of 24,950 individuals had TSH measurements and answered thyroid questions and thus were eligible for analysis on thyroid dysfunction, while in the analysis of diabetes mellitus and blood pressure (BP), 33,734 individuals were included in all.

Self-rated health

The first question in the main questionnaire in HUNT2, answered before attending the examination stations, was “How is your health at the moment?”, with answer alternatives ‘very good’, ‘good’, ‘not so good’ and ‘poor’. This short version of SRH measure is shown to be a valid predictor of mortality. We dichotomised the answers into ‘good’ (very good, good) and ‘poor’ (not so good, poor). Dichotomisation of multinomial SRH is commonly performed, and has been validated by Manor et al.

Thyroid function

The participants answered questions on the history of hypothyroidism and hyperthyroidism, goitre, other thyroid diseases and treatment with thyroxin, radiiodine, surgery or thyreostatic medication.

Serum TSH and free T4 were analysed at the hormone laboratory, Aker University Hospital, Norway. The laboratory reference value for TSH, as defined prior to the survey, was 0.2–4.5 mU/L and for free T4 8–20 pmol/L. If TSH was <0.2 or >4 mU/L, and/or if the participant reported any thyroid disease, serum free T4 was also measured.

Individuals reporting no previous thyroid disease and having TSH within the reference range were categorised as ‘no thyroid disease’ and chosen as the reference category. No previous thyroid disease combined with TSH >4.5 mU/L and free T4 <8 pmol/L was defined as unknown hypothyroidism. No previous thyroid disease combined with TSH >4.5 mU/L and free T4 8–20 pmol/L was defined as subclinical hypothyroidism. Individuals reporting hypothyroidism and use of thyroxin were classified as having known hypothyroidism, regardless of the TSH and T4 levels. Affirmative answers to other thyroid-related questions or measures outside the reference range in the remainders were classified as other thyroid dysfunction.

Diabetes mellitus

Diabetes mellitus was assessed through self-report and blood samples. Serum glucose was analysed at Levanger Hospital, Norway. Those reporting no diabetes and having normal glucose levels (<5.5 mmol/L) were classified as ‘no diabetes’ and were chosen as the reference category. No self-reported diabetes and non-fasting glucose >11 mmol/L was categorised as unknown diabetes, whereas no diabetes and non-fasting glucose 5.5–11 mmol/L was categorised as probable diabetes. Self-reported diabetes was classified as known diabetes regardless of the glucose level.

Blood pressure

In the questionnaire, participants were asked about the doctor’s advice after the latest BP measurement prior to participation in HUNT. The answer categories were: ‘no follow-up and no medication necessary’, ‘recommended follow-up examination but not to take medicine’, ‘start or continue taking medicine for high blood pressure’ or ‘never measured’. At HUNT2, mean systolic and mean diastolic arterial BP of measurement 2 and 3 was categorised into normal (systolic (s) BP<140 mm Hg and diastolic (d) BP<90 mm Hg), mild hypertension (sBP 140–159 mm Hg and dBP<100 mm Hg or sBP<140 mm Hg and dBP 90–99 mm Hg), moderate hypertension (sBP 160–179 mm Hg and dBP<109 mm Hg or sBP<180 mm Hg and dBP 100–109 mm Hg) and severe hypertension (sBP>180 mm Hg or dBP>110 mm Hg). We constructed a new variable to define normotensive (reference), unknown mild and moderate hypertensive, unknown severe hypertensive and known hypertensive persons on the basis of self-report and measures.
### Statistical analysis

The descriptive analyses of the study population were stratified by gender, and we used $\chi^2$ tests to examine any difference in proportions of SRH between the independent variables. Gender-stratified multiple logistic regression was used to estimate OR with 95% CI for good SRH, as a function of thyroid status, diabetes mellitus status and BP status, in separate unadjusted, age-adjusted and multiadjusted analyses for each condition.

Age, smoking, alcohol consumption, body mass index (BMI), working and educational status, and self-reported limiting long-term illness or injury are associated with SRH, as a function of thyroid status, diabetes mellitus status and BP status, in separate unadjusted, age-adjusted and multiadjusted analyses for each condition.

### RESULTS

In all age categories, a higher proportion of men than women reported good SRH ($p<0.001$), and in both sexes the proportion reporting good SRH declined by age ($p<0.002$; table 1). The proportion reporting good SRH was lower in overweight, obese and underweight women than in normal weight women ($p<0.001$). In men, the proportion reporting good SRH declined between the normal weight group and the overweight, obese and underweight groups ($p<0.001$). In previous and current female smokers, a lower proportion reported good SRH compared with non-smokers ($p<0.001$). In men, the proportion reporting good SRH was higher among non-smokers than among previous and current smokers ($p<0.001$), whereas there was no difference between previous and current smokers. The proportion reporting good SRH was higher in moderate and heavy alcohol consumers than in low consumers, increased with education and was higher for participants in paid work ($p<0.001$). Underweight men and persons with ‘any long-term impairment’ had the lowest proportion reporting good SRH of all groups. The proportion reporting good SRH in the overall HUNT2 Study population differed from the proportions reported in persons without thyroid disease and normotensive persons ($p<0.01$), but not from persons without diabetes mellitus. However, the absolute differences were small.

In all fully adjusted regression models, the AUC was 0.80. Unadjusted, the AUC ranged from 0.61 to 0.63.

There was no multicollinearity between the independent variables.

### Thyroid function

Thyroid dysfunctions, known and unknown, were more often observed among women than men ($p<0.001$; table 1). Women with known hypothyroidism had a lower OR of reporting good SRH than women without thyroid disease in the adjusted analyses. However, women with unknown or subclinical hypothyroidism had an 84% and 48% higher OR, respectively, of reporting good SRH compared with the OR of women without thyroid disease (table 2). The association between thyroid function and SRH was basically unchanged after inclusion of confounder variables. Corresponding, but non-significant, associations were found among men.

### Diabetes mellitus

The prevalence of unknown, probable and known diabetes was slightly higher in men than in women ($p<0.001$; table 1). Women with known diabetes mellitus had a lower OR of good SRH than those without diabetes in the adjusted analyses, whereas in women with unknown or possible diabetes mellitus, the ORs of good SRH were similar to the ORs among persons without diabetes in the adjusted analyses (table 2). In the adjusted analyses, the association between unknown and probable diabetes mellitus with poor SRH, found in the
crude analyses, disappeared when age was included in the model in women and men, but also by inclusion of working status alone in women. In men, the association of diabetes status with SRH differed by levels of education. Among men without higher education (12 years or less), the ORs of good SRH were as in the main effect model (table 2). However, in men with higher education, the ORs of good SRH were barely significantly lower among men with unknown diabetes (OR 0.29 (95% CI 0.09 to 1.00)) and among men with possible diabetes (OR 0.79 (95% CI 0.63 to 1.00)) compared with men without diabetes. Among men with known diabetes in this stratum, the OR of good SRH was 0.31 (95% CI 0.17 to 0.54) compared with men without diabetes.

**Blood pressure**
The prevalence of unknown mild and moderate hypertension was higher in men than in women (p<0.001). Unknown severe hypertension and known hypertension

| Table 1 | Good SRH by sex and characteristics of the study population |
|---------|----------------------------------------------------------|
| **Women (n=17 514)** | **Men (n=16 220)** |
| **Study population (n=33 734)** | **n** | **Per cent** | **SRH good (%)** | **n** | **Per cent** | **SRH good (%)** |
| **Age group (years)** | | | | | | |
| 40–50 | 7058 | 40.3 | 77.6 | 6517 | 40.2 | 81.7 |
| 51–60 | 5709 | 32.6 | 64.4 | 5328 | 32.8 | 72.1 |
| 61–70 | 4747 | 27.1 | 56.6 | 4375 | 27.0 | 59.6 |
| **BMI (kg/m²)** | | | | | | |
| <18.5 | 6821 | 0.6 | 58.4 | 4804 | 0.2 | 42.9 |
| 18.5–24.9 | 7026 | 39.1 | 72.8 | 8694 | 29.7 | 75.3 |
| 25.0–29.9 | 3489 | 40.3 | 68.5 | 2635 | 53.8 | 73.6 |
| >30 (0.4% missing) | 104 | 20.0 | 56.5 | 35 | 16.3 | 64.8 |
| **Smoking status** | | | | | | |
| Never smoked daily | 6973 | 40.1 | 70.3 | 4849 | 30.1 | 80.0 |
| Previous daily smoker | 4651 | 26.7 | 68.0 | 6105 | 37.9 | 69.8 |
| Daily smoker (0.7% missing) | 5763 | 33.1 | 64.3 | 5172 | 32.0 | 69.1 |
| **Alcohol use** | | | | | | |
| None to low intake | 14 888 | 88.7 | 66.7 | 11 488 | 73.2 | 71.0 |
| Moderate intake | 1471 | 8.8 | 76.8 | 2839 | 18.1 | 78.7 |
| High intake (3.7% missing) | 430 | 2.6 | 76.3 | 1375 | 8.8 | 78.3 |
| **Educational level (years)** | | | | | | |
| <10 | 8133 | 48.5 | 60.5 | 5711 | 36.5 | 63.1 |
| 10–12 | 5682 | 33.9 | 72.8 | 6615 | 42.2 | 76.0 |
| >12 (3.8% missing) | 2962 | 17.7 | 80.0 | 3399 | 21.3 | 84.7 |
| **Employed** | | | | | | |
| Yes | 11 539 | 67.2 | 77.1 | 12 309 | 77.1 | 79.9 |
| No (1.8% missing) | 5627 | 32.8 | 49.0 | 3665 | 22.9 | 49.2 |
| **Any long-term impairment** | | | | | | |
| No | 10 348 | 59.1 | 85.9 | 9912 | 63.0 | 88.7 |
| Yes (4.1% missing) | 6275 | 35.8 | 39.8 | 5829 | 37.0 | 46.0 |
| **Thyroid function** | | | | | | |
| No thyroid disease | 14 373 | 86.2 | 68.7 | 7804 | 94.3 | 72.1 |
| Unknown hypothyroidism | 107 | 0.6 | 78.5 | 16 | 0.2 | 68.8 |
| Subclinical hypothyroidism | 466 | 2.8 | 75.0 | 150 | 1.8 | 66.4 |
| Known hypothyroidism | 858 | 5.1 | 48.9 | 124 | 1.5 | 58.1 |
| Other thyroid dysfunction (1.3% missing) | 872 | 5.2 | 61.4 | 180 | 2.2 | 56.2 |
| **Diabetes mellitus** | | | | | | |
| No diabetes | 11 279 | 64.6 | 69.4 | 9196 | 56.9 | 74.6 |
| Unknown diabetes | 46 | 0.3 | 52.2 | 88 | 0.5 | 67.8 |
| Probable diabetes | 5728 | 32.8 | 65.9 | 6392 | 39.6 | 71.5 |
| Known diabetes (0.4% missing) | 395 | 2.3 | 43.1 | 482 | 3.0 | 49.5 |
| **Blood pressure status** | | | | | | |
| Normotensive | 9135 | 52.6 | 72.4 | 6858 | 42.7 | 77.5 |
| Unknown mild/moderate hypertension | 4473 | 25.8 | 67.9 | 5343 | 33.3 | 74.7 |
| Unknown severe hypertension | 403 | 2.4 | 70.7 | 349 | 2.2 | 73.8 |
| Known hypertension (0.9% missing) | 3327 | 19.2 | 54.0 | 3498 | 21.8 | 59.6 |
| **Overall study population, HUNT2** | 34 332 | 97.3 | 70.3 | 30 378 | 98.4 | 74.9 |

BMI, body mass index; HUNT, Nord-Trendelag Health Study; SRH, self-rated health.
Table 2  The association between self-rated health and thyroid function, diabetes mellitus and blood pressure

|                          | Women, OR (95% CI) | Men, OR (95% CI) |
|--------------------------|--------------------|-------------------|
|                          | n                  | Crude             | Age adjusted | Multiple adjusted |
| Thyroid function         |                    |                   |              |                   |
| No thyroid dysfunction   | 12 476             | 1.00              | 1.00         | 1.00              |
| Unknown hypothyroidism   | 92                 | 1.66 (1.05 to 2.64)| 2.00 (1.25 to 3.19)| 1.84 (1.02 to 3.33)| 14                  | 0.85 (0.30 to 2.45)| 0.92 (0.31 to 2.72) | 1.28 (0.35 to 4.65) |
| Subclinical hypothyroidism| 394                | 1.37 (1.10 to 1.69)| 1.49 (1.20 to 1.85)| 1.48 (1.13 to 1.94)| 128                | 0.77 (0.54 to 1.08) | 0.88 (0.62 to 1.24) | 1.13 (0.72 to 1.76) |
| Known hypothyroidism     | 718                | 0.44 (0.38 to 0.50)| 0.48 (0.41 to 0.55)| 0.49 (0.41 to 0.59)| 107                | 0.54 (0.37 to 0.77) | 0.63 (0.43 to 0.91) | 0.69 (0.44 to 1.09) |
| Other thyroid dysfunction| 729                | 0.72 (0.63 to 0.83)| 0.77 (0.67 to 0.89)| 0.77 (0.65 to 0.93)| 163                | 0.50 (0.37 to 0.67) | 0.52 (0.38 to 0.71) | 0.58 (0.41 to 0.84) |
| Diabetes mellitus        |                    |                   |              |                   |
| No diabetes              | 9946               | 1.00              | 1.00         | 1.00              |
| Unknown diabetes         | 39                 | 0.48 (0.27 to 0.86)| 0.61 (0.34 to 1.10)| 0.66 (0.32 to 1.37)| 82                  | 0.72 (0.46 to 1.13) | 0.88 (0.55 to 1.39) | 1.03 (0.59 to 1.81) |
| Probable diabetes        | 4797               | 0.85 (0.80 to 0.91)| 0.94 (0.88 to 1.01)| 1.01 (0.92 to 1.10)| 5759                | 0.86 (0.80 to 0.92) | 0.94 (0.88 to 1.01) | 0.99 (0.91 to 1.08) |
| Known diabetes           | 318                | 0.33 (0.27 to 0.41)| 0.42 (0.34 to 0.51)| 0.53 (0.41 to 0.69)| 395                | 0.33 (0.28 to 0.40) | 0.42 (0.35 to 0.51) | 0.55 (0.43 to 0.70) |
| Blood pressure           |                    |                   |              |                   |
| No hypertension          | 8180               | 1.00              | 1.00         | 1.00              |
| Unknown mild/moderate hypertension | 3787 | 0.81 (0.75 to 0.87)| 1.01 (0.93 to 1.09)| 1.10 (0.99 to 1.22)| 4837                | 0.86 (0.79 to 0.93) | 1.01 (0.92 to 1.10) | 1.01 (0.92 to 1.12) |
| Unknown severe hypertension | 325 | 0.92 (0.74 to 1.15)| 1.34 (1.08 to 1.68)| 1.52 (1.14 to 2.02)| 308                | 0.85 (0.77 to 1.08) | 1.27 (0.99 to 1.62) | 1.48 (1.09 to 2.02) |
| Known hypertension       | 2745               | 0.45 (0.41 to 0.49)| 0.59 (0.54 to 0.65)| 0.69 (0.61 to 0.77)| 3118                | 0.43 (0.39 to 0.47) | 0.54 (0.50 to 0.60) | 0.64 (0.57 to 0.72) |

OR of good self-rated health and 95% CIs, crude, age adjusted, and adjusted for age, other long-term illness or injury that impairs function in everyday life, smoking habits, alcohol use, educational level, work status and body mass index. Cases with missing data were excluded from the analyses.
were equally distributed between women and men (table 1). Women with known hypertension had a lower OR of reporting good SRH than normotensive women in the adjusted analyses. The figures were similar in men (table 2). In contrast, compared with normotensive women, those with unknown severe hypertension had a 52% higher OR of reporting good SRH, with similar figures in men. Persons with unknown mild and moderate hypertension reported good SRH, similar to the normotensive ones. Adjusted for age, the association between unknown mild and moderate hypertension and poor SRH disappeared simultaneously; unknown severe hypertension became associated with good SRH in women. In men, age had to be added along with either education or working status to achieve the latter association.

Additional analyses
Women with poor SRH had more than six times the OR of those with good SRH to have had a medical consultation during the last year; OR 6.29 (95% CI 5.47 to 7.22). For men, the corresponding OR was 5.53 (95% CI 4.86 to 6.29). After exclusion of persons with diagnosed thyroid disease, diabetes mellitus, known hypertension and ‘any long-term disease’, the corresponding OR was 3.71 (95% CI 2.90 to 4.73), with similar figures in men.

**DISCUSSION**

This large population-based study showed that persons with known thyroid dysfunction, diabetes mellitus and hypertension were less likely to report good SRH than those without such conditions. Less expected, persons with unknown and subclinical hypothyroidism were more likely to report good SRH than those without thyroid disease. Similarly, those with unknown severe hypertension were more likely to report good SRH, compared with persons with normal BP. In general, persons with unknown diabetes and unknown mild/moderate hypertension reported good health, just like the reference group.

In general, of the confounders, age seemed to influence the association between disease status and SRH most when adjusted for. Age was found to explain the association of poor SRH with unknown and probable diabetes, and with unknown mild and moderate hypertension. In women, age even contributed to an association between unknown severe hypertension and good SRH. There seemed to be a linear decrease by age categories in the association with good SRH. The way age is interpreted the association between disease and SRH makes these findings reasonable.

Although a qualitative and quantitative measure of association, the estimated ORs in our study will, if interpreted as relative risks, overestimate the case, because the prevalence of good SRH is high in all groups. 

The main strengths of this study were: the number of participants, that the diseases we studied were high prevalent and that we could assume representativeness to the general population regarding the variables included. It is known that individuals with a high burden of symptoms are less likely to attend surveys, but so far there has been little evidence that non-participation on this basis introduces substantial bias in associational studies. We studied diseases with a generally low symptom burden and expect selection bias to be negligible.

The main limitation was possibly that we relied on self-reported data on independent and dependent variables. The validity of self-reported measures relevant for this study is questionable. However, in case of any misclassification, it should be non-differential, thus should only cause an underestimation of the associations found.

There is always a possibility of residual confounding in non-randomised study designs, and owing to the observational, cross-sectional design, we cannot assume a causal relationship.

Bias due to differential detection of disease in the study population could lead to a type 1 error. Hypothyroidism and diabetes mellitus are often associated with vague symptoms such as tiredness and weakness. These symptoms are strongly associated with reduced SRH. It is most likely that presenting such symptoms for the general practitioner (GP) would result in measurements of TSH, free T4 and serum glucose, thus revealing any related dysfunction. Low self-perceived health increases the probability of visiting a GP. Social security covers most of the costs related to clinical measurements and blood sampling in Norway; thus, we expect GPs to have a low threshold to measure thyroid function, BP or glucose levels. People who do not consult their GP will not have diseases with mild or no symptoms diagnosed, and their personality could be characterised by a less worrying and more optimistic attitude to health being reflected in better SRH.

On the other hand, the association between known disease and poor SRH could in fact be explained physiologically due to the pathological effect of disease. Lack of a corresponding association between ignored, but prevalent, disease and poor SRH is not in line with this hypothesis, raising the question of a possible adverse effect of disease labelling. However, confounding by severity of disease cannot be ruled out.

Owing to the low number of persons having unknown hypothyroidism and diabetes mellitus, the results should be interpreted with caution. Owing to the other hand, there were high numbers in the subclinical and probable groups, and analyses of these groups did not show any associations with poor SRH, also raising questions of a possible disease labelling effect.

The fact that the HUNT2 survey was carried out nearly 20 years ago raises a question of generalisability to today’s population. Stability of SRH over time has not been investigated in our study population, although it has been investigated among adolescents. We do not expect the association between low burden and subclinical disease...
with SRH to be time dependent to the extent that it would change our results considerably. Neither do we expect the changes in prevalence of most explanatory variables to influence the associations found.

Consistent findings regarding unknown, subclinical and probable disease versus known disease could indicate a potential adverse effect of disease labelling. Although early detection of disease is protective in morbidity and mortality for many diseases, low SRH is also shown to be associated with morbidity and mortality.\(^{25–27}\) This is an important aspect in the debate of presymptomatic case finding.

The BMJ’s Too Much Medicine campaign aims to highlight the threat to human health posed by overdiagnosis and the waste of resources on unnecessary care (http://www.bmj.com/too-much-medicine). American data have shown that the majority of all healthcare includes preference-sensitive and supply-sensitive services. The extent of these services varies greatly without necessarily leading to better health.\(^{47,48}\) A great deal of activity in such services is based on identifying subclinical disease. The negative health effect this might have, modulated through reduced SRH, can explain why the negative health effect and have a negative influence on people’s general and self-perceived health causing more harm than good.\(^{15}\)

Of ethical reasons, the possible causal effect of disease labelling on SRH is impossible to assess in a randomised controlled trial. Our study emphasised the need for more prospective research to investigate the potential health effects of disease labelling and early diagnosis.

**CONCLUSION**

Our data suggest that early identification of disease may imply a negative effect on SRH, and to the extent that SRH has been associated with greater mortality, this may lead to harm. However, as it is also known that diseases such as diabetes and hypertension also lead to increased mortality when detected after cardiovascular and metabolic complications have developed, it remains to be seen whether an early identification or a late detection strategy would provide optimal health for the population.

**Acknowledgements** The Nord-Trøndelag Health Study (The HUNT Study) is a collaboration between the HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology NTNU), the Nord-Trøndelag County Council, the Central Norway Health Authority and the Norwegian Institute of Public Health. The authors would like to thank Bjørn Olav Asvold for his contribution in planning the thyroid part of the study.

**Contributors** SF, AL and SK have been active supervisors in the study conception, design, conduct, interpretation and reporting. PJ analysed the data and drafted the manuscript. Critical revisions were carried out by all supervisors and all authors approved the final version of the manuscript. SF, AL, SK and PJ are joint guarantors.

**Funding** PJ received a PhD grant, funded by the Norwegian University of Science and Technology, NTNU.

**Competing interests** None.

**Ethics approval** The study was approved by the Regional Committee for Medical Research. All participants signed a written informed consent.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) license, which permits others to distribute, remix, adapt, build upon this work for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/3.0/

**REFERENCES**

1. Ziemer DC, Miller CD, Rhee MK, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. *Diabetes Educ* 2005;31:664–71.
2. Borzécki AM, Wong AT, Hickey EC, et al. Hypertension control: how well are we doing? *Arch Intern Med* 2003;163:2705–11.
3. Androz V, Egger A, Dua U. Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes. *J Manag Care Pharm* 2006;12:303–9.
4. Liddy C, Singh J, Hogg W, et al. Quality of cardiovascular disease care in Ontario, Canada: missed opportunities for prevention—a cross sectional study. *BMJ Cardiovasc Disord* 2012;12:74.
5. Hirschmehlmann AG, Mizrachi T, Severin A, et al. Reducing clinical inertia in hypertension treatment: a pragmatic randomized controlled trial. *J Clin Hypertens (Greenwich)* 2012;14:322–9.
6. Alkerwi AA, Pagny S, Lair M-L, et al. Level of unawareness and management of diabetes, hypertension, and dyslipidemia among adults in Luxembourg: findings from ORISCAV-LUX Study. *PLoS ONE* 2013;8:e57920.
7. Khan N, Chockalingam A, Campbell NR. Lack of control of high blood pressure and treatment recommendations in Canada. *Can J Cardiol* 2002;18:857–81.
8. Hetlevik I, Holmen J, Kruger O, et al. Fifteen years with clinical guidelines in the treatment of hypertension—still discrepancies between intentions and practice. *Scand J Prim Health Care* 1997;15:134–40.
9. Hetlevik I, Holmen J, Midtbjell K. Treatment of diabetes mellitus—physicians’ adherence to clinical guidelines in Norway. *Scand J Prim Health Care* 1997;15:193–97.
10. Petursson H, Getz L, Sigurdsson JA, et al. Current European guidelines for management of arterial hypertension: are they adequate for use in primary care? *Modelling study based on the Norwegian HUNT 2 population*. *BMC Fam Pract* 2009;10:70.
11. Petursson H, Getz L, Sigurdsson JA, et al. Can individuals with a significant risk for cardiovascular disease be adequately identified by combination of several risk factors? *Modelling study based on the Norwegian HUNT 2 population*. *J Eval Clin Pract* 2009;15:103–9.
12. Getz L, Sigurdsson JA, Hetlevik I, et al. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. *BMJ* 2005;331:551–4.
13. Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. *JAMA* 1999;282:1458–65.
14. Smith CM. Origin and uses of primary non-nocere—above all, do no harm! *J Clin Pharmacol* 2005;45:371–7.
15. Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. *BMJ* 2012;344:e3502.
16. Milunpalo S, Vuori I, Oja P, et al. Self-rated health status as a health measure: the predictive value of self-reported health status on the use of physician services and on mortality in the working-age population. *J Clin Epidemiol* 1997;50:517–28.
17. Meurer LN, Layde PM, Guse CE. Self-rated health status: a new vital sign for primary care? *WMJ* 2001;100:35–9.
18. Bowling A. Just one question: if one question works, why ask several? J Epidemiol Community Health 2005;59:342–5.
19. Lundberg C, Manderbacka K. Assessing reliability of a measure of self-rated health. Scand J Soc Med 1996;24:218–24.
20. Bopp M, Braun J, Gutzwiller F, et al. Health risk or resource? Gradual and independent association between self-rated health and mortality persists over 30 years. PLoS ONE 2012;7:e30795.
21. Moller L, Kristensen TS, Holnagel H. Self rated health as a predictor of coronary heart disease in Copenhagen, Denmark. J Epidemiol Community Health 1996;50:423–8.
22. Kaplan GA, Goldberg DE, Everson SA, et al. Perceived health status and morbidity and mortality: evidence from the Kuopio Ischaemic Heart Disease Risk Factor Study. Int J Epidemiol 1996;25:259–65.
23. Kroksdat S, Johnsen R, Westin S. Social determinants of disability pension: a 10-year follow-up of 62,000 people in a Norwegian county population. Int J Epidemiol 2002;31:1183–91.
24. Halford C, Wallman T, Welin L, et al. Effects of self-rated health on sick leave, disability pension, hospital admissions and mortality. A population-based longitudinal study of nearly 15,000 observations among Swedish women and men. BMC Public Health 2012;12:1103.
25. Latham K, Peek CW. Self-rated health and morbidity onset among late midlife US adults. J Gerontol B Psychol 2013;68:107–16.
26. Benyamini Y, Idler EL. Community studies reporting association between self-rated health and mortality—additional studies, 1995 to 1998. Res Aging 1999;21:392–401.
27. Nielsen AB, Siersma V, Hiort LC, et al. Self-rated general health among 40-year-old Danes and its association with all-cause mortality at 10-, 20-, and 29 years’ follow-up. Scand J Public Health 2008;36:3–11.
28. Schou MB, Kroksdat S, Westin S. How is self-rated health associated with mortality? Tidsskr Nor Laegeforen 2006;126:2644–7.
29. Barger SD, Muldoon MF. Hypertension labelling was associated with poorer self-rated health in the third US National Health and Nutrition Examination Survey. J Hum Hypertens 2006;20:117–23.
30. Bloom JR, Montrossa S. Hypertension labelling and sense of well-being. Am J Public Health 1981;71:1228–32.
31. Moun M, Naess S, Sorensen T, et al. Hypertension labeling, life events and psychological well-being. Psychol Med 1990;20:635–46.
32. Macdonald LA, Sackett DL, Haynes RB, et al. Labelling in hypertension: a review of the behavioral and psychological consequences. J Chronic Dis 1984;37:933–42.
33. Bianchi GP, Zaccheroni V, Solaroli E, et al. Health-related quality of life in patients with thyroid disorders—a study based on Short-Form 36 and Nottingham Health Profile Questionnaires. Qual Life Res 2004;13:45–54.
34. Holmen J, Midtjell K, Krüger O, et al. The Nord-Trondelag Health Study 1996–2006 (HUNT 2): objectives, methods, and participation. Nor Epidemiol 2003;13:19–32.
35. Kroksdat S, Langhammer A, Hveem K, et al. Cohort profile: the HUNT Study, Norway. Int J Epidemiol 2013;42:968–77.
36. Schnittker J, Bacak V. The increasing predictive validity of self-rated health. PLoS ONE 2014;9:e84933.
37. Idler EL, Benyamini Y. Self-rated health and mortality: a review of twenty-seven community studies. J Health Soc Behav 1997;38:21–37.
38. Manor O, Matthews S, Power C. Dichotomous or categorical response? Analysing self-rated health and lifetime social class. Int J Epidemiol 2000;29:149–57.
39. Bjoro T, Holmen J, Kruger O, et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol 2000;143:839–47.
40. Girón P. Determinants of self-rated health in Spain: differences by age groups for adults. Eur J Public Health 2012;22:36–40.
41. Davies HTO, Cromptie IK, Tavakoli M. When can odds ratios mislead? BMJ 1998;316:989–91.
42. Langhammer A, Kroksdat S, Romundstard P, et al. The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. BMC Med Res Methodol 2012;12:143.
43. Mollarius A, Janson S. Self-rated health, chronic diseases, and symptoms among middle-aged and elderly men and women. J Clin Epidemiol 2002;55:364–70.
44. Hansen AH, Halvorsen PA, Ringberg U, et al. Socio-economic inequalities in health care utilisation in Norway: a population based cross-sectional survey. BMC Health Serv Res 2012;12:336.
45. Vingilis E, Wade T, Seeley J. Predictors of adolescent health care utilization. J Adolesc Health 2007;30:773–800.
46. Breidablik H-J, Meland E, Lydersen S. Self-rated health during adolescence: stability and predictors of change (Young-HUNT study, Norway). Eur J Public Health 2009;19:73–8.
47. Welch HG, Sharp SM, Gottlieb DJ, et al. Geographic variation in diagnosis frequency and risk of death among Medicare beneficiaries. JAMA 2011;305:1113–18.
48. Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. Ann Intern Med 2003;138:288–98.
49. Wennberg JE. Tracking medicine. A researcher’s quest to understand health care. Oxford: Oxford University Press, 2010.